Clinical Pharmacy Program Guidelines for Repatha

<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Repatha (evolocumab)</td>
</tr>
<tr>
<td>Markets in Scope</td>
<td>Arizona, California, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Rhode Island, Pennsylvania CHIP, South Carolina</td>
</tr>
<tr>
<td>Issue Date</td>
<td>5/2015</td>
</tr>
<tr>
<td>Pharmacy and Therapeutics Approval Date</td>
<td>12/2019</td>
</tr>
<tr>
<td>Effective Date</td>
<td>2/2020</td>
</tr>
</tbody>
</table>

1. **Background:**

Repatha™ (evolocumab) is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody indicated:

- to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease,
- as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C)
- as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C

Coverage requests for the use of Repatha for the primary prevention of cardiovascular events and/or for the lowering of low-density lipoprotein cholesterol in patients with primary hyperlipidemia who do not have heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) will be denied as the use of PCSK9 inhibitors in this population is not supported by the 2018 American College of Cardiology/American Heart Association Cholesterol Clinical Practice Guidelines.

2. **Coverage Criteria:**
A. **Hyperlipidemia**

1. **Initial Therapy**

   a. **Repatha** will be approved based on **all** of the following criteria:

      (1) **One** of the following diagnoses:

         (a) Heterozygous familial hypercholesterolemia (HeFH) as confirmed by **one** of the following*:

            i. **Both** of the following:

               1. Pre-treatment LDL-C greater than 190 mg/dL (greater than 155 mg/dL if less than 16 years of age)

                  -AND-

               2. **One** of the following:

                  a. Family history of myocardial infarction in first-degree relative < 60 years of age
                  b. Family history of myocardial infarction in second-degree relative < 50 years of age
                  c. Family history of LDL-C greater than 190 mg/dL in first- or second-degree relative
                  d. Family history of familial hypercholesterolemia in first- or second-degree relative
                  e. Family history of tendinous xanthomata and/or arcus cornealis in first- or second degree relative

            -OR-

            ii. **Both** of the following:

               1. Pre-treatment LDL-C greater than 190 mg/dL (greater than 155 mg/dL if less than 16 years of age)

                  -AND-

               2. Submission of medical records (e.g., chart notes, laboratory values) documenting **one** of the following:

                  a. Functional mutation in LDL, apoB, or PCSK9 gene*
                  b. Tendinous xanthomata
c. Arcus cornealis before age 45

-OR-

(b) Atherosclerotic cardiovascular disease (ASCVD) as confirmed by one of the following:

i. Acute coronary syndromes
ii. History of myocardial infarction
iii. Stable or unstable angina
iv. Coronary or other arterial revascularization
v. Stroke
vi. Transient ischemic attack
vii. Peripheral arterial disease presumed to be of atherosclerotic origin

-AND-

(2) Submission of medical records (e.g., chart notes, laboratory values) documenting one of the following [prescription claims history may be used in conjunction as documentation of medication use, dose, and duration]:

(a) Patient has been receiving at least 12 consecutive weeks of high-intensity statin therapy [i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg] and will continue to receive high-intensity statin at maximally tolerated dose

-OR-

(b) Both of the following:

i. Patient is unable to tolerate high-intensity statin as evidenced by one of the following intolerable and persistent (i.e. more than 2 weeks) symptoms:

- Myalgia (muscle symptoms without CK elevations)
- Myositis (muscle symptoms with CK elevations < 10 times upper limit of normal [ULN])

-AND-

ii. One of the following:

a. Patient has been receiving at least 12 consecutive weeks of moderate-intensity statin [i.e. atorvastatin 10-20 mg, rosvu
rosuvastatin 5-10 mg, simvastatin ≥ 20 mg, pravastatin ≥ 40 mg, lovastatin 40 mg, Lescol XL (fluvastatin XL) 80 mg, fluvastatin 40 mg twice daily or Livalo (pitavastatin) ≥ 2 mg] and will continue to receive a moderate-intensity statin at maximally tolerated dose

-OR-

b. Patient has been receiving at least 12 consecutive weeks of low-intensity statin [i.e. simvastatin 10 mg, pravastatin 10-20 mg, lovastatin 20 mg, fluvastatin 20-40 mg, or Livalo (pitavastatin) 1 mg] therapy and will continue to receive a low-intensity statin at maximally tolerated dose

-OR-

(c) Patient is unable to tolerate low or moderate-, and high-intensity statins as evidenced by one of the following:

i. One of the following intolerable and persistent (i.e. more than 2 weeks) symptoms for low or moderate-, and high-intensity statins:

1. Myalgia (muscle symptoms without CK elevations)
2. Myositis (muscle symptoms with CK elevations < 10 times upper limit of normal [ULN])

-OR-

ii. Patient has a labeled contraindication to all statins as documented in medical records

-OR-

iii. Patient has experienced rhabdomyolysis or muscle symptoms with statin treatment with CK elevations > 10 times ULN

-AND-

(3) One of the following:

(a) Submission of medical record (e.g., laboratory values) documenting one of the following LDL-C values while on maximally tolerated lipid lowering therapy within the last 120 days:
i. LDL-C $\geq$ 100 mg/dL with ASCVD

ii. LDL-C $\geq$ 130 mg/dL without ASCVD

-OR-

(b) Both of the following:

i. Submission of medical record (e.g., laboratory values) documenting one of the following LDL-C values while on maximally tolerated lipid lowering therapy within the last 120 days:

1. LDL-C between 70 mg/dL and 99 mg/dL with ASCVD

2. LDL-C between 100 mg/dL and 129 mg/dL without ASCVD

-AND-

ii. Submission of medical record (e.g., chart notes, laboratory values) documenting one of the following [prescription claims history may be used in conjunction as documentation of medication use, dose, and duration]:

1. Patient has been receiving at least 12 consecutive weeks of ezetimibe (Zetia®) therapy as adjunct to maximally tolerated statin therapy

-OR-

2. Patient has a history of contraindication or intolerance to ezetimibe

-AND-

(4) Used as an adjunct to a low-fat diet and exercise

-AND-

(5) Prescribed by one of the following:

(a) Cardiologist
(b) Endocrinologist
(c) Lipid specialist

-AND-
(6) Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

-AND-

(7) Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

*Results of prior genetic testing can be submitted as confirmation of diagnosis of HeFH, however please note that UnitedHealthcare does not currently cover genetic testing for evidence of an LDL-receptor mutation, familial defective apo B-100 or a PCSK9 mutation.

Authorization will be issued for 12 months

2. Reauthorization

a. Repatha will be approved based on all of the following criteria:

   (1) Patient continues to receive statin at maximally tolerated dose (unless patient has documented inability to take statins)

   -AND-

   (2) Patient is continuing a low-fat diet and exercise regimen

   -AND-

   (3) Prescribed by one of the following:

      (a) Cardiologist
      (b) Endocrinologist
      (c) Lipid specialist

   -AND-

   (4) Submission of medical records (e.g. chart notes, laboratory values) documenting LDL-C reduction while on Repatha therapy

   -AND-
(5) Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

-AND-

(6) Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

Authorization will be issued for 12 months

B. Homozygous Familial Hypercholesterolemia

1. Initial Therapy

   a. Repatha will be approved based on all of the following criteria:

      (1) Diagnosis of homozygous familial hypercholesterolemia (HoFH) as confirmed by submission of medical records (e.g., chart notes, laboratory values) documenting both of the following:**

         (a) One of the following:

             i. Pre-treatment LDL-C greater than 500 mg/dL
             ii. Treated LDL-C greater than 300 mg/dL

         -AND-

         (b) One of the following:

             i. Xanthoma before 10 years of age
             ii. Evidence of heterozygous familial hypercholesterolemia (HeFH) in both parents

         -AND-

      (2) Used as an adjunct to a low-fat diet and exercise

      -AND-

      (3) Patient is receiving other lipid-lowering therapy (e.g., statin, ezetimibe, LDL apheresis)
(4) Prescribed by **one** of the following:

(a) Cardiologist  
(b) Endocrinologist  
(c) Lipid specialist  

(5) Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor  

(6) Not used in combination with Juxtapid (lomitapide)  

(7) Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided.

**Results of prior genetic testing can be submitted as confirmation of diagnosis of HoFH, however please note that UnitedHealthcare does not currently cover genetic testing for evidence of an LDL-receptor mutation, familial defective apo B-100 or a PCSK9 mutation.**

Authorization will be issued for 12 months.

2. **Reauthorization**

   a. **Repatha** will be approved based on **all** of the following criteria:

      (1) Patient is continuing a low-fat diet and exercise regimen  

      (2) Patient continues to receive other lipid-lowering therapy (e.g., statin, LDL apheresis)  

      (3) Submission of medical records (e.g. chart notes, laboratory values)
documenting LDL-C reduction while on Repatha therapy

-AND-

(4) Prescribed by one of the following:

(a) Cardiologist
(b) Endocrinologist
(c) Lipid specialist

-AND-

(5) Not used in combination with another proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor

-AND-

(6) Not used in combination with Juxtapid (lomitapide)

-AND-

(7) Prescriber attests to the following: the information provided is true and accurate to the best of their knowledge and they understand that UnitedHealthcare may perform a routine audit and request the medical information necessary to verify the accuracy of the information provided

Authorization will be issued for 12 months.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. References:


Confidential and Proprietary, © 2020 UnitedHealthcare Services Inc.


<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization – Repatha (evolocumab)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Change Control</strong></td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Change</td>
</tr>
<tr>
<td>5/2015</td>
<td>New program.</td>
</tr>
<tr>
<td>5/2015</td>
<td>Added examples of atherosclerotic cardiovascular disease.</td>
</tr>
<tr>
<td>9/2015</td>
<td>Revised clinical criteria to include combination use of high-intensity statin or documented intolerance to high-, moderate- and low intensity statin therapy to achieve the maximally tolerated statin therapy.</td>
</tr>
<tr>
<td>11/2015</td>
<td>Added step therapy requirement language for Primary Hyperlipidemia</td>
</tr>
<tr>
<td>1/2016</td>
<td>Removed continuation of therapy criterion.</td>
</tr>
<tr>
<td>8/2016</td>
<td>Add requirement of Praluent failure at maximum labeled dosing, Updated reference.</td>
</tr>
<tr>
<td>12/2016</td>
<td>Modified medical record criteria to include review of prescription claims history. Updated references.</td>
</tr>
<tr>
<td>3/2017</td>
<td>Changed initial authorization duration to 12 months for all indications</td>
</tr>
<tr>
<td>11/2017</td>
<td>Updated medical record requirement, modified criteria for HeFH diagnosis, modified previous statin requirement requiring failure, intolerance to high intensity and either moderate or low intensity statin. Modified target LDL values and ezetimibe trial requirement. Extended timeline for lipid panel submission to 120 days. Added physician attestation criterion. Updated references.</td>
</tr>
<tr>
<td>11/2018</td>
<td>Revised background based on package insert updates. Updated references. Removed Kynamro since medication is being removed from the market.</td>
</tr>
<tr>
<td>1/2019</td>
<td>Removed step through Praluent for hyperlipidemia.</td>
</tr>
</tbody>
</table>